KROS Stock Analysis: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$11.19
0.19 (1.73%)
▲
5d:
+11.57%
30d:
+0.0%
90d:
+1.82%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KROS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $11.19, which is considered extended relative to its 30-day fair value range of $10.13 to $11.13.
Technical Outlook: Technically, KROS is in a strong downtrend. The price is approaching resistance at $11.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.83 (+98.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KROS is in a strong downtrend. The price is approaching resistance at $11.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KROS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.83 (+98.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.13 -
$11.13
Company Quality Score
61/100
(BUY)
Options IV Signal
21th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 21th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 98.5% below Wall St target ($21.83)
Trading Range Analysis
30-Day Trading Range
$10.13 -
$11.13
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.79
(7.0%)
Support & Resistance Levels
Support Level
$9.69
Resistance Level
$11.44
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.97
Wall Street Target
$21.83
(+98.5%)
Revenue Growth (YoY)
-99.8%
Profit Margin
-256.6%
Share & Embed Analysis
Last updated: June 24, 2026 12:45 PM ET
Data refreshes hourly during market hours. Next update: 1:45 PM
Data refreshes hourly during market hours. Next update: 1:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jean Jacques Bienaime
BUY
1000 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
